CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...